Swiss National Bank Bio Atla, Inc. Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$2.13 - $5.38 $106,926 - $270,076	-50,200 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$4.38 - $18.78 $33,288 - $142,728	7,600 Added 17.84%	50,200 $251,000
Q3 2021 Nov 08, 2021	BUY	$29.44 - $43.74 $724,224 - $1.08 Million	24,600 Added 136.67%	42,600 $1.25 Million
Q2 2021 Aug 06, 2021	BUY	$38.07 - $56.17 $685,260 - $1.01 Million	18,000 New	18,000 $763,000

23.4M

30.8K

57K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $14.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.